Updated Bayesian network meta-analysis on the efficacy and safety of PD-1 versus PD-L1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer.

Patients with PD-L1 expression levels < 1%, PD-1 + Chemo showed a trend of disadvantage (OS: HR 1.3; PFS: HR 1.2), whereas for patients with PD-L1 expression levels ≥ 1%, PD-1 + Chemo showed a trend of advantage (OS: HR 0.85; PFS: HR 0.85).

also in 53,322 other papers